The goal of Data and Safety Monitoring (DSM) at City of Hope (COH) is to provide oversight of clinical trialsconducted at City of Hope Comprehensive Cancer Center independent of the protection of human subjectsafforded through the COH Institutional Review Board (IRB) and the scientific review afforded through theProtocol Review and Monitoring System via the Cancer Protocol Review and Monitoring Committee(CPRMC). This function is organized around the Cancer Center's Data and Safety Monitoring Board(DSMB). The principal role of the DSMB is to review all protocol-specific data and safety monitoring plans,periodic reports from protocol management teams, deviation reports, and adverse event reports frominvestigators as they are submitted to determine the scientific impact of these toxicities on the conduct of theclinical trial in which they occurred. In addition, the DSMB regularly reviews audits of ongoing, high-risk,institutional cancer clinical trials for compliance with federal regulations and Good Clinical Practice (GCP)guidelines. Staff members of the Office of Clinical Research Quality Assurance (OCRQA) perform bothdetailed audits of ongoing in-house studies as part of the institution's clinical research qualityassurance program as well as providing effective reporting of deviations in the conduct of all cancer clinicaltrials as they may occur. This level of review provides an independent means of confirming the efficacy ofthe investigational treatment programs ongoing in the Cancer Center. The total annual budget for DSM (5.42FTEs) is $ 450,592; CCSG funding is requested for $ 59,749, or 13% of the total.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA033572-25
Application #
7714136
Study Section
Subcommittee G - Education (NCI)
Project Start
2008-09-01
Project End
2012-11-30
Budget Start
2008-09-01
Budget End
2008-11-30
Support Year
25
Fiscal Year
2008
Total Cost
$42,379
Indirect Cost
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Salgia, Ravi; Kulkarni, Prakash; Gill, Prakash S (2018) EphB4: A promising target for upper aerodigestive malignancies. Biochim Biophys Acta Rev Cancer 1869:128-137
Choi, Audrey H; O'Leary, Michael P; Lu, Jianming et al. (2018) Endogenous Akt Activity Promotes Virus Entry and Predicts Efficacy of Novel Chimeric Orthopoxvirus in Triple-Negative Breast Cancer. Mol Ther Oncolytics 9:22-29
Kumar, B; Garcia, M; Weng, L et al. (2018) Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion. Leukemia 32:575-587
Zhou, Jiehua; Lazar, Daniel; Li, Haitang et al. (2018) Receptor-targeted aptamer-siRNA conjugate-directed transcriptional regulation of HIV-1. Theranostics 8:1575-1590
Ding, Yuan Chun; Adamson, Aaron W; Steele, Linda et al. (2018) Discovery of mutations in homologous recombination genes in African-American women with breast cancer. Fam Cancer 17:187-195
Kurata, Jessica S; Lin, Ren-Jang (2018) MicroRNA-focused CRISPR-Cas9 library screen reveals fitness-associated miRNAs. RNA 24:966-981
Hardwick, Nicola R; Frankel, Paul; Ruel, Christopher et al. (2018) p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy. Clin Cancer Res 24:1315-1325
Dietze, Eric C; Chavez, Tanya A; Seewaldt, Victoria L (2018) Obesity and Triple-Negative Breast Cancer: Disparities, Controversies, and Biology. Am J Pathol 188:280-290
Kingsmore, Kathryn M; Vaccari, Andrea; Abler, Daniel et al. (2018) MRI analysis to map interstitial flow in the brain tumor microenvironment. APL Bioeng 2:
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096

Showing the most recent 10 out of 1396 publications